• In a multicentre, single-arm, open-label phase 2 study, we enrolled adult patients with Philadelphia-chromosome-negative, primary refractory or relapsed (first relapse within 12 months of first remission, relapse within 12 months after allogeneic haemopoietic stem-cell transplantation [HSCT], or no response to or relapse after first salvage therapy or beyond) leukaemia. (nih.gov)
  • 12 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT. (nih.gov)
  • Short time to relapse and refractory disease at the time of autologous HSCT remain the most important risk factors. (nih.gov)
  • Data suggest that young patients with recurring disease following autologous HSCT, as well as some patients with multiple relapses and selected patients with refractory lymphoma, might benefit from allogeneic HSCT, but relapse remains the major challenge. (nih.gov)
  • CHICAGO - Lenalidomide (Revlimid) is a vital component of early therapy and maintenance for patients with multiple myeloma, but patients in first relapse who have disease that is refractory to lenalidomide have few good options for subsequent lines of therapy and a generally poor prognosis. (medscape.com)
  • For the CARTITUDE-4 trial, the investigators enrolled patients aged 18 years or older with lenalidomide-refractory multiple myeloma who had experienced relapse after one to three prior lines of therapy that included a prosteasome inhibitor and immunomodulator. (medscape.com)
  • In patients with relapse disease, we see that they were given often induction chemotherapy, and then they went through sometimes transplant and then a maintenance phase. (ajmc.com)
  • The relapsed/refractory patients in early relapse, I think, are so different. (ajmc.com)
  • It's been a really exciting, I think, landscape and that relapse remitting or relapsed/refractory setting. (ajmc.com)
  • Relapse means the disease comes back after a remission following treatment. (schoolandyouth.org)
  • The single-arm, open-label, multicenter phase II study included patients aged 3 to 23 years who were primary refractory, refractory to chemotherapy after their first relapse, relapsed after second-line therapy, or ineligible for an allogeneic stem cell transplant. (ascopost.com)
  • We excluded patients with primary disease relapse or progression before aGvHD or who underwent more than one allo-HCT. (thejh.org)
  • FDA medical oncologists discuss the Sept. 13, 2018, approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy cell leukemia. (fda.gov)
  • Today, we'll be discussing the recent approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy cell leukemia. (fda.gov)
  • Moxetumomab pasudotox-tdfk is for adult patients with relapsed or refractory hairy cell leukemia who have had treatment with at least two prior systemic therapies, including at least one purine nucleoside analog. (fda.gov)
  • Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia (NCI-10-C-0025). (cancer.gov)
  • NCI researchers think that combining bendamustine and rituximab may prove effective in treating patients with multiply relapsed or refractory hairy cell leukemia. (cancer.gov)
  • Treating Multiply Relapsed or Refractory Hairy Cell Leukemia was originally published by the National Cancer Institute. (cancer.gov)
  • It was the aim of this paper to identify prognostic factors in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas, treated by radioimmunotherapy (RIT) with radioiodinated human/murine chimeric anti-CD20 monoclonal antibody rituximab ( 131 I-rituximab). (karger.com)
  • Earlier application of transplantation or development of additional effective antineoplastic modalities will be required to improve the results of transplantation for patients with advanced Hodgkin's disease. (umn.edu)
  • Bcell non-Hodgkin's lymphoma is a malignant, monoclonal (arising from a single cell) proliferation of lymphocytes that is preceded by lymphadenopathy and characterized by varying, less predictable spread than Hodgkin's disease. (glutenfreeworks.com)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (schoolandyouth.org)
  • 1. In patients believed to have celiac disease who have persistent or recurrent symptoms or signs, the initial diagnosis of celiac disease should be confirmed by review of prior diagnostic testing, including serologies, endoscopies and histologic findings. (gastro.org)
  • 2. In patients with confirmed celiac disease with persistent or recurrent symptoms or signs (nonresponsive celiac disease), ongoing gluten ingestion should be excluded as a cause of these symptoms with serologic testing, dietitian review and detection of immunogenic peptides in stool or urine. (gastro.org)
  • High-dose corticosteroids (CS) are the cornerstone to avoid complications and the progression to the chronic recurrent phase of the disease. (bmj.com)
  • Hairy cell leukemia is usually treated with a chemotherapy drug called cladribine when signs or symptoms of the disease develop, such as low blood cell counts, recurrent infections, or a swollen spleen. (cancer.gov)
  • The intention of this study is to describe the impact and underlying potential basis of the prostate-specific antigen (PSA) flare-up phenomenon in patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel-based chemotherapy. (springer.com)
  • ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. (nih.gov)
  • CONCLUSION: Subcutaneous epcoritamab resulted in deep and durable responses and manageable safety in highly refractory patients with large B-cell lymphoma, including those with prior CAR T-cell exposure. (bvsalud.org)
  • Aim: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). (bvsalud.org)
  • Oudard S, Banu E, Beuzeboc P et al (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. (springer.com)
  • Kreis W, Budman DR, Fetten J et al (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. (springer.com)
  • 4. Use flow cytometry, immunohistochemistry and T-cell receptor rearrangement studies to distinguish between subtypes of refractory celiac disease and to exclude enteropathy-associated T-cell lymphoma. (gastro.org)
  • 5. Perform small bowel imaging with capsule endoscopy and computed tomography or magnetic resonance enterography to exclude enteropathy-associated T-cell lymphoma and ulcerative jejunoileitis at initial diagnosis of type 2 refractory celiac disease. (gastro.org)
  • Complications of H pylori include peptic ulcer disease (PUD), gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma. (medscape.com)
  • CLL can be grouped with small lymphocytic lymphoma (SLL) as one disease with two clinical presentations. (wikipedia.org)
  • This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors. (bcan.org)
  • The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D). (bcan.org)
  • This is an open-label, multicenter, Phase 1/1b study of RMC-5552 monotherapy in participants with advanced relapsed or refractory solid tumors. (bcan.org)
  • The study will include 2 components: 1) a Dose-Escalation Component for participants with relapsed or refractory solid tumors and 2) a Dose-Expansion Component for participants with relapsed or refractory solid tumors harboring certain specific mutations/rearrangements that result in hyperactivation of the mTOR pathway. (bcan.org)
  • Antitumor necrosis factor antibodies and calcineurin inhibitors have shown good therapeutic efficacy for steroid-refractory ulcerative colitis (UC). (hindawi.com)
  • This study aimed to compare therapeutic efficacies between IFX- and Tac-based strategies for steroid-refractory UC. (hindawi.com)
  • The findings of our study showed that IFX and Tac have similar short-term therapeutic efficacy for steroid-refractory UC. (hindawi.com)
  • However, 20-40% of patients fail to respond to corticosteroids (steroid-refractory UC) or fail to maintain remission without them (steroid-dependent UC) [ 1 - 5 ]. (hindawi.com)
  • Previously, most patients with steroid-refractory or steroid-dependent UC would avoid total colectomy. (hindawi.com)
  • On the other hand, anti-TNF antibodies, such as infliximab (IFX) or adalimumab, and calcineurin inhibitors, such as cyclosporin A (CsA) or tacrolimus (Tac), have shown good salvage therapeutic efficacies for inducing remission in steroid-refractory UC. (hindawi.com)
  • However, whether IFX or CsA should be chosen to treat patients with steroid-refractory UC remains controversial. (hindawi.com)
  • Therefore, Tac is now strongly regarded as one of the main therapeutic options when treating steroid-refractory UC. (hindawi.com)
  • Accordingly, patients must be re-challenged with higher corticosteroid doses to fulfill the criteria of steroid refractory aGvHD prior to pursuing clinical trial enrollment. (thejh.org)
  • Histologically confirmed metastatic melanoma with measurable (by RECIST v1.1), stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease that is accessible for injection. (mayo.edu)
  • Subject has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists. (bcan.org)
  • High-Risk relapsed/refractory metastatic Neuroblastoma (HRrrm-NBL) has a poor prognosis and high-activity 131 I-mIBG therapy could represent a promising strategy. (researchsquare.com)
  • Ovasave® (TxCell SA, Valbonne, France) could offer a welcome option for some patients with refractory Crohn's disease (CD) who have exhausted conventional therapies. (ecri.org)
  • Then there are the patients who are truly refractory to most therapies - they just don't respond to anything. (medscape.com)
  • it was approved in March 2022 by the US Food and Drug Administration for use in patients with refractory/relapsed multiple myeloma who have already tried four or more therapies. (medscape.com)
  • Ibrutinib, the first BTK inhibitor that was introduced in clinical practice, dramatically improved both the progression-free (PFS) and overall survival (OS) of CLL patients compared to conventional therapies, both in the first-line and relapsed/refractory setting. (bjh.be)
  • Through research, we can identify new treatment options for digestive disease patients. (gastro.org)
  • Macroscopic observation of endobronchial Microascus cirrosus lesion in patient in France with refractory microascus bronchopulmonary infection before (A) and after (B) olorofim treatment. (cdc.gov)
  • Further assessment of blinatumomab treatment earlier in the course of the disease and in combination with other treatment approaches is warranted. (nih.gov)
  • Also commenting on the new results, ASCO Expert Oreofe Odejide, MD, of the Dana-Farber Cancer Institute in Boston, said in a statement: "Lenalidomide has become a foundation of care for people with myeloma, but as its use has expanded, so has the number of patients whose disease will no longer respond to the treatment. (medscape.com)
  • To synthesise published findings for treatment with SIH for refractory heroin-dependence through systematic review and meta-analysis, and to examine the political and scientific response to these findings. (cambridge.org)
  • SIH is found to be an effective way of treating heroin dependence refractory to standard treatment. (cambridge.org)
  • Treatment continues for 6 courses in the absence of disease progression. (knowcancer.com)
  • from date of registration to date of first observation of progressive disease, deathe due to any cause, or early discontinuation of treatment. (knowcancer.com)
  • CONCLUSIONS IABCP can be an effective means of controlling refractory ventricular arrhythmia, allowing time for the institution of more definitive treatment. (bmj.com)
  • Consideration of IABCP was given to any patient with ventricular arrhythmia refractory to conventional treatment, but who would be suitable for more definitive treatment or who might otherwise have a reasonable quality of life if the arrhythmia were controlled. (bmj.com)
  • In recent years, treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), either as monotherapy or in combination with other drugs, have become the standard of treatment. (researchgate.net)
  • Jeffrey Matous, MD, leads a panel discussion surrounding the use of bispecifics treatment of relapsed / refractory multiple myeloma. (ajmc.com)
  • Hello, and welcome to this AJMC® Peer Exchange® program entitled "Treatment with Bispecifics In Relapsed/Refractory Multiple Myeloma. (ajmc.com)
  • BTK inhibition first proved its worth in the relapsed/refractory setting and in specific subgroups of patients with high-risk cytogenetic features, but recent data also support the broader use of this strategy in the first-line treatment of CLL patients. (bjh.be)
  • Here, we report the use of the Kampo extract of shinbuto for successful treatment of and abdominal pain in a patient with Milroy's disease. (elsevierpure.com)
  • Subject's prior treatment should include all approved regimens that have demonstrated a survival advantage for the subject's disease, stage, and line of therapy. (bcan.org)
  • Treatment response was classified in Progression and Stable Disease (PD and SD), Partial and Complete Response (PR and CR) and correlated to the value of D Lesion value. (researchsquare.com)
  • Doris K. Hansen, MD, discussed results of an efficacy analysis examining the BCMA-directed CAR T-cell therapy idecabtagene vicleucel in real-world treatment of patients with relapsed/refractory multiple myeloma. (cancernetwork.com)
  • Fortunately, treatment for relapsed/refractory CLL has significantly improved in recent years, with data showing prolonged progression-free survival in this population. (medscape.com)
  • Corticosteroid use as an initial therapy, along with other immunosuppressives, is recommended in many guidelines for treatment of different autoimmune diseases with moderate or high activity owing to their ability to rapidly control the inflammation and its symptoms. (dovepress.com)
  • We present the case of a 78-year-old man with a history of seronegative polyarthritis that was refractory to treatment with several biological agents for a duration of 5 years prior to presentation to the emergency department with stroke. (lu.se)
  • This is a 26-week, double-blind, randomized, placebo-controlled two-arm parallel-group trial of d-cycloserine, a pharmacological treatment selected based on positive results from previous preclinical and clinical studies, for the treatment of chronic, refractory low back pain (CBP). (clinicaltrials.gov)
  • Early-stage CLL in asymptomatic cases responds better to careful observation, as there is no evidence that early intervention treatment can alter the course of the disease. (wikipedia.org)
  • Refractory means the disease has not responded to treatment. (schoolandyouth.org)
  • Of them, 16 patients discontinued treatment before infusion and the majority (9 patients) did so due to rapid progression of their disease or deterioration in their clinical status. (ascopost.com)
  • Editor's note: On July 12, 2017, the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously in favor of CTL019 (tisagenlecleucel) for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia. (ascopost.com)
  • A small percentage of individuals have symptoms that persist months or years after treatment, which is called post-treatment Lyme disease syndrome. (medlineplus.gov)
  • Individuals with post-treatment Lyme disease syndrome report ongoing exhaustion (fatigue), muscle and joint achiness, headache, or difficulty concentrating even after treatment with antibiotics, when there is no evidence of the bacteria in the body. (medlineplus.gov)
  • These guidelines for the treatment of patients with sexually transmitted diseases (STDs) were developed by staff members of CDC after consultation with a group of invited experts who met in Atlanta on January 19-21, 1993. (cdc.gov)
  • Treatment protocols for hairy cell leukemia (HCL) are provided below, including those for initial treatment, resistant disease, variant HCL, and relapsed/refractory HCL. (medscape.com)
  • CV004 trade name] may also be used in the treatment of coronavirus disease 2019 (COVID-19) in adult and adolescent patients (aged 12 years and older with body weight of at least 40 kg) who require supplemental oxygen therapy. (who.int)
  • They're the patients who always do partially well on any agent that they're on, but they never quite get over the finish line of low disease activity or remission. (medscape.com)
  • UPDATED RESULTS from the ELIANA clinical trial of CTL019 (tisagenlecleucel)-an investigational chimeric antigen receptor (CAR) T-cell therapy-found that remission rates are maintained at 6 months in relapsed/refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia. (ascopost.com)
  • Experts share 10 pieces of best practice advice for diagnosing and treating refractory celiac disease. (gastro.org)
  • If villous atrophy persists or the initial diagnosis of celiac disease was not confirmed, consider other causes of villous atrophy, including common variable immunodeficiency, autoimmune enteropathy, tropical sprue and medication-induced enteropathy. (gastro.org)
  • 3. For patients with nonresponsive celiac disease, after exclusion of gluten ingestion, perform a systematic evaluation for other potential causes of symptoms, including functional bowel disorders, microscopic colitis, pancreatic insufficiency, inflammatory bowel disease, lactose or fructose intolerance and small intestinal bacterial overgrowth. (gastro.org)
  • Type 1 refractory celiac disease is characterized by a normal intraepithelial lymphocyte population and type 2 is defined by the presence of an aberrant, clonal intraepithelial lymphocyte population. (gastro.org)
  • 6. Complete a detailed nutritional assessment with investigation of micronutrient and macronutrient deficiencies in patients diagnosed with refractory celiac disease. (gastro.org)
  • The latest research on genetics and celiac disease. (idnahealth.com.au)
  • Important to read if any member of the family has celiac disease or any other autoimmune disease. (idnahealth.com.au)
  • The project will conduct a multicentre, randomized, placebo-controlled, double-blinded Phase II clinical study to provide proof of concept and clinical validation for a new, percutaneous, cost-efficient therapy for refractory angina patients. (europa.eu)
  • Because the affected areas of the CNS differ from patient to patient, clinical signs and symptoms of the disease are variable, and diagnosis requires a high level of suspicion. (medscape.com)
  • Today our panel of experts will explore the clinical impact of relapsed/refractory multiple myeloma. (ajmc.com)
  • Based on promising (pre-)clinical data and the favourable toxicity profile, we performed a phase II clinical trial with the JAK inhibitor ruxolitinib in patients with relapsed or refractory cHL (r/r cHL). (uni-koeln.de)
  • Olbert PJ, Hegele A, Kraeuter P et al (2006) Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. (springer.com)
  • Clinical evidence implicates periods of psychological stress in Crohn's disease exacerbation, and disturbances in the gut microbiome might contribute to the pathogenic mechanism. (nature.com)
  • After a few years, the patient returned with refractory infectious, demonstrating on clinical examination, submandibular fistula with spontaneous drainage and reconstruction plate externalization in parasymphysis region of previous surgery. (bvsalud.org)
  • Chronic beryllium (7440417) disease or berylliosis was reviewed with regard to occurrence, clinical signs, diagnostic strategies, and preventive measures. (cdc.gov)
  • These findings together with a recent report of four patients with Crohn's disease and refractory anaemia suggests that the association may be more than coincidental and may be immune mediated. (bmj.com)
  • Crohn's disease is an inflammatory disease of the gastrointestinal tract characterized by an aberrant response to microbial and environmental triggers. (nature.com)
  • We conclude that psychological stress impairs IL-22-driven protective immunity in the gut, which creates a favorable niche for the expansion of pathobionts that have been implicated in Crohn's disease. (nature.com)
  • Final results of CARTITUDE-1, reported in a scientific poster at ASCO 2023, showed that almost half of patients (47.5%) who were treated with cilta-cel were free of disease progression at 3 years, and 59.8% had sustained, complete responses. (medscape.com)
  • Although a high unmet need exists for new treatments for refractory CD, the high potential cost of the cell-based immunotherapy, frequency of injections, and lack of long-term efficacy data could temper utilization. (ecri.org)
  • Medical records research - uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best. (mayo.edu)
  • Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. (mayo.edu)
  • Although pentostatin and cladribine provide responses in greater than 85% of patients, and a median progression-free survival of up to 15y, alternative treatments, such as the addition of rituximab, are needed for patients who become refractory to these treatments. (medscape.com)
  • Centers for Disease Control and Prevention. (cdc.gov)
  • SUGGESTED CITATION: Centers for Disease Control and Prevention. (cdc.gov)
  • The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. (cdc.gov)
  • Good afternoon, I am Marcy Friedman and I'm representing the Clinician Outreach and Communication Activity, COCA, with the Emergency Risk Communication branch at the Centers for Disease Control and Prevention. (cdc.gov)
  • Dr. Knust has served as epidemiologist in the Viral Special Pathogens Branch at the Centers for Disease Control and Prevention for seven years. (cdc.gov)
  • Patients with only 1 prior line of therapy were required to be refractory to lenalidomide, and prior anti-CD38 or pomalidomide was not permitted. (pharmacytimes.com)
  • Whereas 79.6% of patients were refractory to lenalidomide, 40% of patients were refractory to a PI, and 42.4% of patients were refractory to both. (pharmacytimes.com)
  • Patients with lenalidomide-refractory multiple myeloma who received a single infusion of ciltacabtagene autoleucel demonstrated a 74% reduction in the risk for disease progression or death compared with patients who received the standard of care. (medscape.com)
  • Our topic today is how to treat patients with refractory or difficult-to-treat rheumatoid arthritis , a problem which faces all of us as rheumatologists on a weekly basis as well as patients who are on their fourth or fifth biologic agent to try to control their rheumatoid arthritis. (medscape.com)
  • Are we dealing with osteoarthritis that may be on the part of the patient or on the part of me being confused for the rheumatoid arthritis disease activity? (medscape.com)
  • If not treated with antibiotics, Lyme disease follows three stages: early localized, early disseminated, and late disseminated infection. (medlineplus.gov)
  • Lyme disease is caused by infection with bacteria rather than by genetic changes. (medlineplus.gov)
  • Those relapses can be biochemical where the paraproteins are just increasing gradually, or they can be symptomatic where they have new bone lesions, kidney disease, or other. (ajmc.com)
  • However, in a significant percentage of patients-especially those with advancedstage HL-the disease relapses or is refractory. (schoolandyouth.org)
  • Heidenreich A, Sommer F, Ohlmann CH et al (2004) Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. (springer.com)
  • Each year approximately 1 million women in the United States experience an episode of symptomatic pelvic inflammatory disease (PID) (*) (1,2). (cdc.gov)
  • A phase 3 study evaluating subcutaneous (SC) daratumumab plus pomalidomide found that daratumumab plus pomalidomide and dexamethasone (D-Pd) significantly reduced the risk of progression or death by 37% in patients with relapsed/refractory multiple myeloma (RRMM) who had received more than or equal to 1 prior line of therapy versus pomalidomide alone, according to data to be presented at the virtual American Society of Hematology (ASH) conference. (pharmacytimes.com)
  • Results of the phase III ASCEND trial demonstrate that the second-generation Bruton's tyrosine kinase inhibitor acalabrutinib significantly reduces the risk of disease progression or death compared to bendamustine or idelalisib in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. (bjh.be)
  • During EHA 2019, the first results of the phase III trial evaluating acalabrutinib in patients with relapsed/refractory CLL were presented. (bjh.be)
  • ASCENC phase 3 study of acalabrutinib vs. investigator's choice of rituximab plus idelalisib or bendamustine in patients with relapsed/refractory CLL. (bjh.be)
  • The patients were randomized 1:1 to Pd ± daratumumab SC, and stratification was based on International Staging System disease stage and number of lines of prior therapy. (pharmacytimes.com)
  • Chronic angina pectoris is a debilitating chronic disease, a subgroup of these patients suffers from refractory angina which unfortunately can't be controlled by medical therapy (angioplasty or surgery). (europa.eu)
  • 120 CCS class 2-3 refractory angina patients will be recruited, which will allow us to assess the benefits of therapy to patients who still have potential to respond to the regenerative therapy. (europa.eu)
  • In addition, the median PFS was longer than for any previously reported therapy for heavily pretreated patients with relapsed/refractory multiple myeloma, the authors said. (medscape.com)
  • Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease of unknown etiology. (hindawi.com)
  • Chronic beryllium disease in the United States. (cdc.gov)
  • Fort Lauderdale, FL-The B?rveldt-250 mm2 Glaucoma Implant (Advanced Medical Optics) seems to be more effective at lowering IOP than the Ahmed S2 Glaucoma Valve (New World Medical Inc.) in adult patients with refractory glaucoma. (ophthalmologytimes.com)
  • Single-agent blinatumomab showed antileukaemia activity in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia characterised by negative prognostic factors. (nih.gov)
  • OBJECTIVE To review the efficacy of intra-aortic balloon counterpulsation (IABCP) in medically refractory ventricular arrhythmia. (bmj.com)
  • To evaluate the safety of intravenous high-dose pulse methylprednisolone succinate (IVHDM) in the management of severe or refractory non-infectious pediatric uveitis. (dovepress.com)
  • Lyme disease is an infectious disease caused by Borrelia burgdorferi bacteria. (medlineplus.gov)
  • Dr. Mertz is a board-certified Sub-specialist in Infectious Diseases and former Chief of the Division of Infectious Diseases at the University of New Mexico Health Sciences Center where he is now working as a retiree. (cdc.gov)
  • From 1999 through April 2016, Dr. Mertz was the principal investigator at the National Institutes of Health International Collaborations in infectious diseases research grant U19/U01 focused on epidemiology, natural history and management of hantavirus cardiopulmonary syndrome in Chile and Panama. (cdc.gov)
  • Acute graft-versus-host disease (aGvHD) remains a barrier to success following allogeneic hematopoietic cell transplant (allo-HCT) [ 1 - 5 ]. (thejh.org)
  • So it makes sense to use rituximab along with pentostatin as a comparator to bendamustine and rituximab for patients with multiply relapsed or refractory disease. (cancer.gov)
  • Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. (nih.gov)
  • This reflects the acute and progressive nature of this disease. (ascopost.com)
  • IVHDM may be a valid therapeutic option for aggressive/refractory pediatric uveitis. (dovepress.com)
  • Vogt-Koyanagi-Harada disease (VKH) is an autoimmune disorder characterised by bilateral granulomatous panuveitis variously associated with extraocular features such as aseptic meningitis, tinnitus, hypoacousia, alopecia, vitiligo and poliosis to configure complete or incomplete forms. (bmj.com)
  • IntroductionRheumatic diseases are autoimmune, inflammatory diseases often associated with cardiovascular (CV) disease, a major cause of mortality in these patients. (researchgate.net)
  • 6 Since then, they have been and are still being used extensively as anti-inflammatory agents for different autoimmune and rheumatological diseases. (dovepress.com)
  • We describe the successful employment of infliximab, an anti-TNFα chimeric antibody, in two patients with refractory VKH. (bmj.com)
  • This complication is called antibiotic-refractory Lyme arthritis. (medlineplus.gov)
  • The utility of Tac for treating refractory UC has been reported in some studies: the short-term response rates range from 55 to 98%, with less severe adverse events than with CsA [ 15 , 16 , 21 - 24 ]. (hindawi.com)
  • Twenty pediatric patients with severe or refractory uveitis who received IVHDM were identified. (dovepress.com)
  • Three variants of the disease are recognized in the literature: severe infantile malignant autosomal recessive, intermediate mild autosomal recessive, and benign autosomal dominant, with the first being the most severe. (bvsalud.org)
  • Healthcare providers should recognize underlying risk factors for severe disease, optimize immune function, and when appropriate, initiate medical countermeasures (such as tecovirimat and vaccinia immunoglobulin) early to prevent or mitigate severe disease. (cdc.gov)
  • According to patient selection criteria, overall and disease-free survival rates after autologous HSCT are 43-95% and 31-70%, respectively. (nih.gov)
  • Promising results are published with other biologics for refractory and multi-resistant cases. (rheumres.org)
  • Ae triseriatus, Culex quinquefasciatus partially refractory and Anopheles quadrimaculatus resistant. (cdc.gov)
  • refractory (heat-resistant applications). (cdc.gov)
  • Refractory uses of chromium include magnesite-chrome firebrick for metallurgical furnace linings and granular chromite for various other heat-resistant applications. (cdc.gov)
  • Inflammatory bowel disease and refractory anaemia (myelodysplasia). (bmj.com)
  • abstract = "Milroy's disease is a hereditary congenital lymphedema caused by lymphatic obstruction. (elsevierpure.com)
  • Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (springer.com)
  • Durability is an important measure for children and young adults with relapsed or refractory B-cell ALL, and we are truly encouraged by the results of this study," said lead investigator Stephan Grupp, MD, PhD , the Yetta Deitch Novotny Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, and Director of the Cancer Immunotherapy Frontier Program at the Children's Hospital of Philadelphia. (ascopost.com)
  • Participants will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first. (bcan.org)
  • The signs and symptoms of Lyme disease result from the body's immune response to the bacteria. (medlineplus.gov)
  • Sometimes we see that there is some polyarticular calcium pyrophosphate deposition disease , maybe a polymyalgia rheumatica overlay, and rethinking the diagnosis can help us move in a direction that's more helpful for the patient. (medscape.com)
  • Conclusions: In countries like Bangladesh diagnosis of Behçet's disease can be delayed. (rheumres.org)
  • These attacks continued in the same frequency for 3 years, so the patient visited a Kampo (traditional Japanese medicine) clinic, where her diagnosis of Milroy's disease-associated diarrhea and abdominal pain was augmented by the Kampo diagnosis of hiesho, suitai (body fluid retention). (elsevierpure.com)
  • When using these guidelines, consideration should be given to the disease prevalence and to other characteristics of the practice setting. (cdc.gov)
  • In patients with impaired left ventricular function, medically refractory ventricular arrhythmia can present a difficult management problem. (bmj.com)
  • A 40-year-old woman had been suffering of many symptoms of Behçet's disease (BD) since her childhood without being diagnosed. (rheumres.org)
  • For progression based solely on worsening of non-target or new, non-measurable disease, confirmation by an additional scan at least 4 weeks after the initial scan unless progression is accompanied by correlative symptoms. (mayo.edu)
  • Two patients with colitis and refractory anaemia requiring multiple transfusions are described. (bmj.com)
  • Beth, would you please start us off with an overview of relapsed/refractory multiple myeloma. (ajmc.com)
  • The longer, and we all obviously know that multiple myeloma continues to be a disease that remains without a cure. (ajmc.com)
  • Major secondary endpoints included overall response rate, rates of very good partial response or better and complete response or better, measurable residual disease‑negativity rate, overall survival, and safety. (pharmacytimes.com)
  • Has measurable disease per RECIST 1.1. (bcan.org)